Cargando…

CTLA-4 polymorphism and primary Sjögren's syndrome: authors' response

Detalles Bibliográficos
Autores principales:	Miceli-Richard, Corinne, Gottenberg, Jacques-Eric, Mariette, Xavier
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206350/ http://dx.doi.org/10.1186/ar2199

Ejemplares similares

CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjögren syndrome
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2007)

CTLA4 polymorphism and primary Sjögren's syndrome
por: Lester, Susan, et al.
Publicado: (2007)

No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2006)

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome
por: Ittah, Marc, et al.
Publicado: (2006)

Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity
por: Sellam, Jérémie, et al.
Publicado: (2009)

Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial
por: Bodewes, Iris L A, et al.
Publicado: (2020)

ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?
por: Payet, J, et al.
Publicado: (2015)

Seasonal effect on fatigue, pain and dryness in primary Sjögren’s syndrome
por: Duret, Pierre-Marie, et al.
Publicado: (2020)

Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine
por: Collins, Alexis, et al.
Publicado: (2021)

Inclusion body myositis and Sjögren’s syndrome: the association works both ways
por: Giannini, Margherita, et al.
Publicado: (2022)

Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
por: Seror, Raphaele, et al.
Publicado: (2022)

Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome
por: Sanosyan, Armen, et al.
Publicado: (2019)

Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2009)

Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2013)

Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis
por: Rivière, Elodie, et al.
Publicado: (2018)

Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort
por: Carvajal Alegria, Guillermo, et al.
Publicado: (2016)

Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome
por: Miceli-Richard, Corinne, et al.
Publicado: (2016)

EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
por: Seror, Raphaèle, et al.
Publicado: (2015)

Cognitive Dysfunction and Dementia in Primary Sjögren's Syndrome
por: Blanc, Frederic, et al.
Publicado: (2013)

Primary Sjogrens Syndrome in a Child
por: Kumar, K. Jagadish, et al.
Publicado: (2015)

Phenotypic switch from non-active primary Sjögren's syndrome to severe systemic Lupus erythematosus after COVID-19 infection in an elderly man
por: Roger, Guillaume, et al.
Publicado: (2021)

Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögren’s syndrome
por: Kawka, Lou, et al.
Publicado: (2023)

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?
por: Devauchelle-Pensec, Valérie, et al.
Publicado: (2015)

Sjögren’s syndrome: state of the art on clinical practice guidelines
por: Romão, Vasco C, et al.
Publicado: (2018)

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019)

CTLA-4 gene polymorphisms are associated with obesity in Turner Syndrome
por: dos Santos, Luana Oliveira, et al.
Publicado: (2018)

Nephrocalcinosis in primary Sjögren's syndrome
por: Gharbi, Chems, et al.
Publicado: (2014)

Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
por: Hassold, Nolan, et al.
Publicado: (2022)

Low Influenza, Pneumococcal and Diphtheria–Tetanus–Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren’s Syndrome: A Cross-Sectional Study
por: Jacques, Morel, et al.
Publicado: (2019)

Primary Sjögren’s syndrome combined with Chlamydia psittaci infection
por: Wang, Gang, et al.
Publicado: (2022)

The role of CTLA-4 in immune regulation
por: Verhagen, Johan, et al.
Publicado: (2008)

Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus
por: Trutschel, Diana, et al.
Publicado: (2022)

Neurological Disorders in Primary Sjögren's Syndrome
por: Tobón, Gabriel J., et al.
Publicado: (2012)

Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms
por: Berry, Andrew, et al.
Publicado: (2008)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

Plasmacytosis and nephrotic syndrome revealing Sjögren’s syndrome
por: LA, Céline, et al.
Publicado: (2020)

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019)

Efficacy of daratumumab in refractory primary Sjögren disease
por: Nocturne, Gaetane, et al.
Publicado: (2023)

Lymphoma Associated with Sjögren’s Syndrome
por: Aktan Köşker, Tuğba, et al.
Publicado: (2013)

Hospitalization Risks for Neurological Disorders in Primary Sjögren’s Syndrome Patients
por: Goulabchand, Radjiv, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_00tscfltqkqq43t8ok2m7s8nk4